Literature DB >> 34934938

New milestones for IOTECH in 2022.

John Haanen1.   

Abstract

Entities:  

Year:  2021        PMID: 34934938      PMCID: PMC8675604          DOI: 10.1016/j.iotech.2021.100060

Source DB:  PubMed          Journal:  Immunooncol Technol        ISSN: 2590-0188


× No keyword cloud information.
  3 in total

1.  Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Piotr Tomczak; Se Hoon Park; Balaji Venugopal; Thomas Ferguson; Yen-Hwa Chang; Jaroslav Hajek; Stefan N Symeonides; Jae Lyun Lee; Naveed Sarwar; Antoine Thiery-Vuillemin; Marine Gross-Goupil; Mauricio Mahave; Naomi B Haas; Piotr Sawrycki; Howard Gurney; Christine Chevreau; Bohuslav Melichar; Evgeniy Kopyltsov; Ajjai Alva; John M Burke; Gurjyot Doshi; Delphine Topart; Stephane Oudard; Hans Hammers; Hiroshi Kitamura; Jens Bedke; Rodolfo F Perini; Pingye Zhang; Kentaro Imai; Jaqueline Willemann-Rogerio; David I Quinn; Thomas Powles
Journal:  N Engl J Med       Date:  2021-08-19       Impact factor: 91.245

2.  Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

Authors:  Nikhil C Munshi; Larry D Anderson; Nina Shah; Deepu Madduri; Jesús Berdeja; Sagar Lonial; Noopur Raje; Yi Lin; David Siegel; Albert Oriol; Philippe Moreau; Ibrahim Yakoub-Agha; Michel Delforge; Michele Cavo; Hermann Einsele; Hartmut Goldschmidt; Katja Weisel; Alessandro Rambaldi; Donna Reece; Fabio Petrocca; Monica Massaro; Jamie N Connarn; Shari Kaiser; Payal Patel; Liping Huang; Timothy B Campbell; Kristen Hege; Jesús San-Miguel
Journal:  N Engl J Med       Date:  2021-02-25       Impact factor: 91.245

3.  The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration.

Authors:  S Banerjee; K H J Lim; K Murali; K Kamposioras; K Punie; C Oing; M O'Connor; E Thorne; B Devnani; M Lambertini; C B Westphalen; P Garrido; T Amaral; G Morgan; J B A G Haanen; C Hardy
Journal:  ESMO Open       Date:  2021-02-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.